Scholarlink

<p>Melanoma progression is characterized by complex molecular mechanisms and immune dysregulation. In this study, we investigated the role of pyroptosis, a caspase-dependent and pro-inflammatory form of programmed cell death, as a potential modulator of anti-tumor immunity. Analysis of datasets from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) revealed that B lymphocyte tyrosine kinase (BLK), a member of the Src family kinases, is significantly downregulated in melanoma samples. Notably, elevated BLK expression was positively associated with improved overall survival. Functional assays in human melanoma cell lines revealed that BLK overexpression significantly suppressed melanoma cell proliferation, migration, invasion, and was associated with pyroptosis, characterized by Caspase-3 activation and subsequent GSDME cleavage. Moreover, analysis of clinical cohort data (TCGA) revealed that high BLK expression correlated with enhanced infiltration of CD8⁺ T cells, NK cells, and M1 macrophages, suggesting an immunostimulatory role in the tumor microenvironment. Importantly, higher BLK expression level was associated with increased sensitivity to immune checkpoint blockade therapies. These findings position BLK as a key regulator of melanoma progression by promoting pyroptosis and strengthening anti-tumor immunity, thus offering a promising biomarker and a potential avenue for enhancing immunotherapeutic efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

BLK suppresses melanoma progression and improves prognosis via pyroptosis regulation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月1日

查看全文
  • Zhe Zhou,
  • Susi Zhu,
  • Xingxing Jian,
  • Xu Zhang,
  • Xiang Chen

摘要

Melanoma progression is characterized by complex molecular mechanisms and immune dysregulation. In this study, we investigated the role of pyroptosis, a caspase-dependent and pro-inflammatory form of programmed cell death, as a potential modulator of anti-tumor immunity. Analysis of datasets from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) revealed that B lymphocyte tyrosine kinase (BLK), a member of the Src family kinases, is significantly downregulated in melanoma samples. Notably, elevated BLK expression was positively associated with improved overall survival. Functional assays in human melanoma cell lines revealed that BLK overexpression significantly suppressed melanoma cell proliferation, migration, invasion, and was associated with pyroptosis, characterized by Caspase-3 activation and subsequent GSDME cleavage. Moreover, analysis of clinical cohort data (TCGA) revealed that high BLK expression correlated with enhanced infiltration of CD8⁺ T cells, NK cells, and M1 macrophages, suggesting an immunostimulatory role in the tumor microenvironment. Importantly, higher BLK expression level was associated with increased sensitivity to immune checkpoint blockade therapies. These findings position BLK as a key regulator of melanoma progression by promoting pyroptosis and strengthening anti-tumor immunity, thus offering a promising biomarker and a potential avenue for enhancing immunotherapeutic efficacy.